Kuros starts Phase IIb clinical trial with KUR-211 for diabetic foot ulcers

07-Jul-2009 - Switzerland

Kuros Biosurgery AG announced that it has treated the first patient in a Phase IIb clinical trial investigating KUR­211 (Viz.I-020201) in the treatment of diabetic foot ulcers.

KUR-211 consists of a modified variant of platelet-derived growth factor (PDGF) incorporated into a fibrin sealant and is applied to the wound as a foam. The Kuros “TG-hook” technology enables the PDGF to be covalently bound into the fibrin matrix and maintained within the applied product allowing its sustained release from the matrix into the wound through enzymatic cleavage. As a result KUR­211 not only provides a matrix into which skin cells can migrate, but it also facilitates the sustained delivery of PDGF. It is hoped that this novel approach may lead to improved wound healing.

This Phase IIb clinical trial is a randomised, multi-center, controlled, parallel group dose-finding study that will evaluate the efficacy and safety of KUR-211 used as an adjunct to standard of care in patients with diabetic foot ulcer. Approximately 210 patients will be recruited at around 30 centers across Europe including Russia. The study will evaluate the effects of KUR-211 in addition to standard of care versus standard of care alone.

Kuros partnered with Baxter International Inc. for the development of KUR-211 under a collaboration and license agreement that was signed in 2005.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

A type of virus present in the gut microbiota is associated with better cognitive ability in humans, mice and flies - The study finds a greater presence of these viruses in people who eat dairy products in their regular diet

A type of virus present in the gut microbiota is associated with better cognitive ability in humans, mice and flies - The study finds a greater presence of these viruses in people who eat dairy products in their regular diet

Study in Spain and Romania confirms radon as second leading cause of lung cancer

Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases - BT-061 in clinical development for the treatment of RA and psoriasis